Shields C B, Reiss S J, Garretson H D
J Neurosurg. 1987 Aug;67(2):187-91. doi: 10.3171/jns.1987.67.2.0187.
Chemonucleolysis with chymopapain has been advocated for the treatment of lumbar disc disease. When polled by a mail questionnaire, 150 consecutive patients who had undergone chemonucleolysis reported an overall success rate of only 40% and a failure rate of 60%. However, 57% of the patients were active or had only mild restriction of daily activities. Of those patients employed prior to injection, only 63% had returned to work. Those with workmen's compensation benefits fared considerably worse than those covered by third-party insurance (17% vs. 51% success). These results cast doubt on the long-term benefits of chymopapain in the treatment of lumbar disc disease.
木瓜凝乳蛋白酶化学髓核溶解术一直被提倡用于治疗腰椎间盘疾病。通过邮寄问卷对150例连续接受化学髓核溶解术的患者进行调查，结果显示总体成功率仅为40%，失败率为60%。然而，57%的患者活动自如或日常活动仅受到轻微限制。在注射治疗前有工作的患者中，只有63%恢复了工作。享受工伤赔偿福利的患者比参加第三方保险的患者情况要差得多（成功率分别为17%和51%）。这些结果使人对木瓜凝乳蛋白酶治疗腰椎间盘疾病的长期疗效产生怀疑。
